Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

June 15, 2024

https://www.globenewswire.com/news-release/2024/06/15/2899255/31990/en/Agios-Presents-Positive-Results-from-Phase-3-ENERGIZE-Study-of-Mitapivat-in-Non-Transfusion-Dependent-Thalassemia-in-Plenary-Session-at-the-European-Hematology-Association-2024-Hyb.html

– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for 
Non-Transfusion-Dependent Alpha- and Beta-Thalassemia –

– Additional ENERGIZE Poster Presentation Highlights Improvements in Fatigue and Exercise Capacity in Patients Treated with Mitapivat Compared to Placebo –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.